BioSpace News Archive

Ardelyx, Inc. today shared data on the investigational use of IBSRELA® (tenapanor) in pediatric patients via two poster presentations presented at the 2023 North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, currently being held in San Diego, California.

Acasti Pharma Inc. today announced that it will host a virtual KOL event titled GTX-104: a potential new treatment standard for rare and life-threatening aSAH on Wednesday, October 11, 2023 at 2:00pm ET.

Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, a leader in data-driven proteomics technology, announced that they have entered into a definitive agreement to combine in an all-stock merger.

IMIDomics Inc. today announced that it has entered into an agreement with WuXi Biologics, a global Contract Research, Development and Manufacturing Organization, aimed at accelerating the development and manufacturing of IMIDomics IMB1001.

Halberd Corporation’s (OTC PINK:HALB) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU) replicated the earlier dramatic results.

Kineta, Inc. announced today the presentation of new preclinical data on the company’s anti-CD27 agonist monoclonal antibodies (mAbs) in development for the treatment of advanced solid tumors at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology.

Femasys Inc. today announced that it will be exhibiting at the annual meeting of the American Society of Reproductive Medicine (ASRM): “The Past, The Present, and The Pipeline”, being held in New Orleans.

Artelo Biosciences, Inc. announced that H.C. Wainwright will be hosting a virtual medical expert webinar on October 11, 2023 at 12:00 p.m. Eastern Time to discuss the current treatment landscape for cancer-related anorexia and cachexia.

China SXT Pharmaceuticals, Inc. today announced that its Board of Directors has set the date of October 5, 2023 to be the effective date for the Company’s one-for-twenty-five reverse stock split of its issued and outstanding ordinary shares.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) is pleased to announce a partnership with New York Cancer & Blood Specialists (NYCBS), a group of leading community cancer centers in the United States, to evaluate the Bria-IMT™ combination with a checkpoint inhibitor in its pivotal Phase 3 registration study in advanced breast cancer patients in New York.